ImmunoCellular Therapeutics (OTCBB: IMUC) issued the following Letter to Shareholders today:
Dear Shareholders,
As the summer comes to a close, I wanted to update you on the Company's accomplishments this year, which set the stage for an exciting fall. The first eight months of the year have been very successful, with the Company attaining many of its goals, despite a very difficult economic environment, which has created challenges for many small biotechnology companies. Today, IMUC is in its best financial position ever and well positioned to validate the success it achieved in a Phase I trial for ICT-107, its dendritic cell-based cancer vaccine product candidate. We expect to begin a Phase II study prior to the end of the year, which will be the broadest and most comprehensive study of the ICT-107 vaccine to date. Some of the recent corporate highlights include: